The secretion of PRL is controlled by different hypothalamic signals. Depending on the experimental model, PRL secretion increases or decreases after activation of N-methyl--aspartic acid and kainate receptors. Recently we have described that activation of -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors inhibits PRL secretion in prepubertal male rats. The aim of present study was to examine (1) the physiological relevance of this finding, (2) the possible age-related changes observed after activation or blockade of AMPA receptors, (3) the specificity of the AMPA effect, (4) the hypothalamic and/or pituitary localization of AMPA action, and (5) the mechanism(s) of action of AMPA agonists.
Introduction
Hypothalamic control of prolactin (PRL) secretion involves different PRL-releasing (PRF) and -inhibitory factors (for review see Neill & Nagy 1994) . Excitatory amino acids (EAAs) are the major activating transmitters in the brain (van den Pol et al. 1990) . In recent years, many authors have firmly established the role of EAA pathways in the control of neuroendocrine function (for review see . The actions of EAAs are mediated by different post-synaptic receptors which include N-methyl -aspartate (NMDA) receptors, kainate (KA) receptors, 2-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, and metabotropic receptors (Collinbridge & Watkins 1994 . Depending on the experimental paradigm, NMDA and KA either stimulated or inhibited PRL secretion (Abbud & Smith 1991 , Luderer et al. 1993 , Carbone et al. 1994 , Pinilla et al. 1996 . It has been proposed that the effects of glutamate agonists on PRL secretion depend on the previous circulating concentrations of the hormone, with a conversion of the PRL response from stimulation when basal secretion is low to an inhibitory effect in hyperprolactinaemic situations (Abbud & Smith 1991) . However, previous data from our laboratory indicated that, at least partially, the dual effect of NMDA on PRL secretion is independent of prior PRL concentrations (Pinilla et al. 1998) .
AMPA receptors are involved in the steroid-induced luteinizing hormone (LH) surge (Ping et al. 1997 ) and activation of AMPA receptors stimulates gonadotrophinreleasing hormone (GnRH) release from rat hypothalamic fragments and from immortalized GnRH neurones (Donoso et al. 1990 , Spergel et al. 1994 , Zuo et al. 1996 . We reported very recently that activation of AMPA receptors stimulates growth hormone (GH) release and inhibits PRL secretion in prepubertal male and female rats (González et al. 1999a,b) . The experiments presented herein were set out to obtain additional information abouth the control of PRL secretion by AMPA receptors. Specifically we examine (1) the physiological relevance of this finding, (2) the possible age-related changes after activation or blockade of AMPA receptors, (3) the specificity of the AMPA effect, (4) the hypothalamic and/or pituitary localization of AMPA action, and (5) the mechanism(s) of action of AMPA agonists.
Materials and Methods

Animals and drugs
Wistar rats born in our laboratory were kept under controlled conditions of light (12 h light:12 h darkness, lights on at 0700 h) and temperature (22 C), with free access to pelleted food (Pacsa Sanders, Seville, Spain) and tap water. On day 1 of life, each dam was left with eight pups. ( )--amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA; an agonist of AMPA receptors), 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo (f) quinoxaline-7-sulfonamide (NBQX; an antagonist of AMPA receptors), dizolcipine maleate (MK-801; an antagonist of NMDA receptors) and domperidone (a dopaminergic antagonist) were purchased from Research Biochemicals International (Natick, MA, USA). Diethyldithiocarbamate (DDC; an inhibitor of dopamine--hydroxylase); -methyl-p-tyrosine ( -MPT; an inhibitor of tyrosine hydroxylase) and 5-hydroxytryptophan methyl ester (5-HTP; a precursor of serotonin synthesis) were obtained from Sigma (Barcelona, Spain). Fluoxetine (an inhibitor of serotonin reuptake) was generously supplied by Dista (Barcelona,Spain). AMPA and NBQX were dissolved initially in a few drops of dimethylsulfoxide and domperidone in a few drops of methanol. Thereafter, the drugs were dissolved in saline up to the working concentration. The doses and route of administration of different drugs as well as the time-points for hormone measurements were selected based on the previously reported effectiveness (Negro-Vilar et al. 1979 , Martin et al. 1995 , Pinilla et al. 1998 , Gonzalez et al. 1999a and the absence of behavioural changes. In addition, to analyse the effectiveness of AMPA to change PRL secretion after blockade of different receptor subtypes as well and in hyper-and hypo-prolactinaemic situations, NBQX, MK-801, -MPT, DDC, 5-HTP and fluoxetine were injected prior to AMPA administration.
Experimental designs
Experimental procedures were approved by the Córdoba University Ethical Committee for animal experimentation and were conducted in accordance with the European Union norms for care and use of experimental animals.
Neonatal and prepubertal males
In experiment 1, 23-day-old male rats (n=10 per group) were killed 15, 30 and 60 min after i.p. injection of AMPA (2·5 or 5 mg/kg) or vehicle and 60 and 120 min after i.p. injection of NBQX (0·25 and 0·50 mg/kg) or vehicle. Special precautions were taken to avoid any stressful influences (e.g. all animals were handled daily for a week before the experiment and killed by the same person, the different drugs being injected at random). Trunk blood was collected in polystyrene tubes and after centrifugation (1600 g at 4 C for 20 min) serum was collected, frozen and stored at 20 C until use. Pituitaries were removed, dissected and homogenized in 1 ml physiological saline containing urea (2·5 mol/l) by ultrasonic treatment (Haggi & Aoki 1981) . Samples were centrifuged for 20 min at 2800 g and the supernatant was frozen at 20 C until analysis for hormone content. In experiment 2, in order to detect the onset of the inhibitory effect of AMPA on PRL secretion, 5-, 10-and 23-day-old males (n=10-12 per group) were decapitated 15 min after administration of 1 or 2·5 mg/kg AMPA. In experiment 3, in order to determine whether the inhibitory effect of AMPA was mediated by its specific receptors, 23-day-old males (n=10 per group) were injected with NBQX (antagonist of AMPA receptors; 0·5 mg/kg) or MK-801 (antagonist of NMDA receptors; 0·25 mg/kg) at 60 min and with vehicle or AMPA (2·5 mg/kg) at 15 min. In experiment 4, in order to detect possible actions of AMPA at pituitary level in the control of PRL secretion, anterior hemipituitaries (10-12 per group) were obtained from 23-dayold male rats and placed in glass scintillation vials (one per vial) in a Dubnoff shaker at 38 C in an atmosphere of 95% O 2 -5% CO 2 . Each vial contained 1 ml Dulbecco's Minimal Essential Medium (DMEM). After preincubation for 60 min, the medium was replaced by fresh medium containing AMPA (10 8 to 10 6 M). Samples of medium were obtained at 60 and 120 min of the incubation period. In experiment 5, in order to determine the possible involvement of dopamine on AMPA effects, 23-day-old males (n=10 per group) were injected with vehicle or domperidone (1 mg/kg at 60 min) and with vehicle or AMPA (2·5 mg/kg at 15 min). Other animals (n=10 per group) were injected with 250 mg/kg -MPT (inhibitor of dopamine synthesis) or 500 mg/kg DDC (inhibitor of dopamine--hydroxylase) 3 h before administration of vehicle or AMPA (2·5 mg/kg) and the animals were killed 15 min later. In experiment 6, in order to evaluate the ability of AMPA to inhibit serotoninstimulated PRL secretion, 23-day-old males (n=10 per group) were injected s.c. with fluoxetine (10 mg/kg) and 5-HTP (100 mg/kg) 45 min before administration of vehicle or AMPA (2·5 mg/kg) and the animals were killed 15 min later.
Adult male rats
In this set of experiments, the role of AMPA receptors in the control of PRL secretion was studied in freely moving adult male rats. In experiment 7, the animals (n=6-8 per group) were implanted with intracardiac canullae under sodium pentobarbital (50 mg/kg) anaesthesia. After surgery, the animals were placed directly in isolation test chambers for 5 days. In order to evaluate the role of AMPA and NBQX administered systemically, the animals were sampled for 2 h at 15-min intervals. At the end of the first hour of sampling, the animals were injected i.p. with vehicle, AMPA (2·5 mg/kg) or NBQX (0·5 mg/kg). In experiment 8, the animals were implanted with intracardiac and i.c.v. canullae under sodium pentobarbital (50 mg/kg) anaesthesia. In order to evaluate the role of NBQX administered i.c.v., groups of male rats (n=10 per group) were sampled at 5-min intervals for periods of 3 h (1000-1300 h) as previously described (Carro et al. 1997) . After the two initial samples, the animals received either vehicle or NBQX (20 nmol in 10 µl) through the i.c.v. route. During the sampling period, the volume of blood withdrawn was replaced hourly by a suspension of blood cells in sterile saline warmed at 38 C. Other animals (n=5-6 per group) were sampled at 15-min intervals for periods of 6 h (1000-1600 h).
PRL measurements
The PRL concentrations were measured in duplicate aliquots using a double-antibody method and radioimmunoassay (RIA) kits supplied by NIH (Bethesda, MD, USA). Rat-PRL-I-6 was labelled with iodine-125 by the chloramine T method (Greenwood et al. 1963 ) and rat-PRL-RP-3 was used as standard. Serum PRL concentrations were measured in 25-50 µl aliquots and media from pituitary incubations were diluted 1/100 and 10 µl of this solution used for PRL measurements. Intra-and interassay variations were 9% and 12% respectively, and assay sensitivity was 10 pg/tube.
Statistical analysis
Data are expressed as means ... Data were homogeneous and no transformation was carried out. Intergroup differences were determined by one-or twoway analysis of variance (ANOVA) followed by Tukey's test. Specifically, we used two-way ANOVA to analyse interaction between different variables in experiment 1 (serum PRL concentrations at different times after different treatments), experiment 2 (serum PRL concentrations at different ages after different treatments), experiment 4 (PRL concentrations after different times of incubation in the presence of different doses of AMPA), and experiments 5 and 6 (effects of AMPA in animals previously treated with different drugs). Assessment of pulsatile PRL secretion was carried out using the ULTRA program (E Van Cauter, Department of Medicine, University of Chicago, Chicago, IL, USA).
Results
Effects of AMPA and NBQX on serum and pituitary PRL concentrations in 23-day-old male rats (experiment 1)
Administration of AMPA decreased PRL concentrations significantly (Pc0·01, two-way ANOVA). The analysis of interactions evidenced that the effect was significant 15 and 30 min after administration of 2·5 or 5 mg/kg AMPA and returned to basal levels 60 min after drug injection (Fig. 1) . Serum concentrations of PRL remained unchanged in male rats 1 and 2 h after administration of NBQX (data not shown). Pituitary concentrations of PRL remained unchanged after AMPA or NBQX administration (data not shown).
Effects of AMPA on serum PRL concentrations in infantile rats (experiment 2)
Serum PRL concentrations were higher in 23-day-old animals than in neonatal ones (Pc0·01, two-way ANOVA). The analysis of interactions evidenced that the inhibitory effect of AMPA was not observed in 5-and 10-day-old males (Table 1) .
Effects of pretreatment with NBQX and MK-801 on the inhibitory action of AMPA on PRL secretion (experiment 3)
Since it has been suggested that the same agonist might bind to more than one receptor subtype (Zanisi et al. 1994) , we checked the effects of AMPA in the presence of NBQX (antagonist of AMPA receptors) and MK-801 (antagonist of NMDA receptors). In this experiment there was evidence that antagonization of NMDA receptors with MK-801 and activation of AMPA receptors significantly (Pc0·01) inhibited PRL secretion, the effects of MK-801 and AMPA being additive. NBQX blocked the AMPA action and the serum PRL concentrations were similar in animals treated with NBQX or NBQX+AMPA ( Table 2) .
Effects of AMPA on PRL secretion by hemipituitaries in vitro (experiment 4)
PRL concentrations in media were significantly higher at 120 min than at 60 min of incubation (Pc0·01, two-way ANOVA). Incubation of pituitary tissue in the presence of AMPA failed to inhibit PRL release. Furthermore, the analysis of interactions indicated a significant increase (Pc0·01) 120 min after incubation with the lowest dose tested (10 8 M) ( Table 3) .
Effects of changes in dopaminergic tone on the inhibitory action of AMPA on PRL secretion (experiment 5)
Domperidone (antagonist of dopaminergic D2 receptors) prompted a clearcut increase (Pc0·01, two-way ANOVA) in serum PRL concentrations. The analysis of interactions showed that the inhibitory effect of AMPA disappeared in domperidone-treated rats (Table 4 ).
-MPT (a blocker of tyrosine hydroxylase that reduced dopamine synthesis) significantly increased serum PRL concentrations and abolished the inhibitory effect of AMPA (Table 4 ). In contrast, animals pretreated with DDC (inhibitor of dopamine--hydroxylase) showed a significant reduction in serum PRL concentrations. In these animals, a further decrease in PRL concentrations was induced by AMPA administration (Table 4) .
Effects of AMPA on serotonin-stimulated PRL secretion (experiment 6)
Serum PRL concentrations increased significantly after administration of fluoxetine and 5-HTP (Pc0·01, twoway ANOVA). The analysis of interactions between treatments evidenced that the serotonin-stimulated PRL release was not inhibited by AMPA (Table 5 ). 
Effects of systemic administration of AMPA and NBQX on PRL secretion in adult male rats (experiment 7)
In freely moving adult male rats, serum PRL concentrations showed a tendency to decrease during the sampling period. Neither AMPA nor NBQX administered systemically affected PRL secretion (data not shown).
Effects of i.c.v. administration of NBQX on PRL secretion in adult male rats (experiment 8)
Vehicle-injected animals sampled for 3 or 6 h showed pulsatile PRL secretion (pulse frequency: 4·77 0·4 pulses/6 h; pulse duration: 63 4·7 min; pulse amplitude: 5·98 3·8 ng/ml; mean PRL levels: 4·43 1·12 ng/ml; through levels 1·38 0·05 ng/ml; area under the curve: 864 136), which remained unaffected after i.c.v. injection of NBQX (20 or 40 nmol) (data not shown).
Discussion
The present results clearly demonstrate that activation of AMPA receptors inhibits PRL secretion in prepubertal male rats, probably through a hypothalamic mechanism (González et al. 1999b) , which suggests a possible sexually dimorphic role of AMPA receptors in the control of PRL secretion, a finding also described for GH (González et al. 1999b) . Activation of AMPA receptors had no effect in neonatal rats as significant inhibition of PRL secretion was not observed on days 5 and 10 of life. This finding is in striking contrast with the effects observed on GH, since AMPA significantly stimulated GH on day 5 (from 15·42 2·56 ng/ml to 146 37 ng/ml 15 min after administration of 1 mg/kg AMPA) (González et al. 1999a) . These results suggest that the acquisition of AMPA receptor-mediated regulatory mechanisms for different pituitary hormones displays a different timing.
In the present study, pulsatile secretory profiles of PRL in adulthood were similar to those previously described (López et al. 1991) . Our results indicate that the role of AMPA receptors in the control of PRL secretion disappeared in adulthood, since neither AMPA nor NBQX affected PRL secretion. Absence of effects were observed after systemic or i.c.v. administration of drugs, indicating that the ineffectiveness of these drugs was independent of their ability to cross the brain-blood barrier. Loss of the effects of AMPA on PRL secretion in adult rats is specific since, in the same experimental paradigm, AMPA administration increased GH secretion (González et al. 1999a) . Our results in adult male rats rats contradict those of Wagner et al. (1994a,b) showing that systemic administration of NBQX decreased serum PRL concentrations. Differences may be due to the very high doses of NBQX (20 and 60 mg/kg) required to detect this phenomenon.
The precise mechanisms involved in the inhibition of PRL secretion after activation of AMPA receptors have yet to be determined. In theory, an inhibitory effect at pituitary level, an increase in dopamine release or a decrease in the secretion of hypothalamic PRFs might be responsible for the inhibitory effect of AMPA. Despite the presence of AMPA receptors in pituitary gland (Kiyama et al. 1993 , Meeker et al. 1994 , Bhat et al. 1995 , Villalobos et al. 1996 , the only pituitary effect observed was a weak stimulatory action after incubation of hemipituitaries with 10 8 M AMPA. The results strongly suggest that the activation of AMPA receptors does not affect the secretion of PRL via a pituitary mechanism.
In order to analyse the involvement of dopamine in the inhibitory actions of AMPA, dopaminergic receptors were blocked with domperidone and dopamine synthesis with -MPT. In these experimental paradigms, AMPA failed to decrease PRL secretion, suggesting that an increase in dopamine release might be involved in the action of AMPA. Further experiments are necessary in order to determine whether activation of AMPA receptors also decreased the secretion of PRFs, such as vasointestinal peptide, thyrotrophin-releasing hormone or the newly characterized PRL-releasing peptide (Kato et al. 1978 , Fagin & Neill 1981 , Hinuma et al. 1998 .
AMPA also failed to reduce PRL secretion in animals pretreated with fluoxetine and 5-HTP. This finding is consistent with our hypothesis that the mechanism behind the action of AMPA involves the release of hypothalamic dopamine since, when dopamine was infused intravenously, elevating its concentration in portal vessels, 5-hydroxytryptamine-induced PRL release was not prevented (Pilotte & Porter 1981) .
The physiological relevance of the inhibitory effect of AMPA on PRL secretion in rats remains to be elucidated. However, the fact that this action is only observed in prepubertal animals opens the possibility that pubertal development might be dependent on the degree of activation of NMDA and AMPA receptors. Activation of NMDA receptors advanced puberty onset through an increase in LH-releasing hormone release (Urbanski & Ojeda 1987 ). In contrast, repeated i.c.v. injections of AMPA to immature female rats diminished PRL and oestradiol secretion and delayed puberty . Since, in these experiments, LH secretion remained unchanged after systemic or i.c.v. administration of AMPA, it is tempting to postulate that the delay of puberty after AMPA treatment is mediated by the decrease in PRL secretion, since it is well known that PRL increased the number of ovarian LH receptors (Advis et al. 1981) , the responsiveness to gonadotrophins (Advis & Ojeda 1978) and advanced the onset of puberty in female and male rats (Clemens et al. 1969 , Aguilar et al.1988 . Experiments are in progress to determine whether activation of AMPA receptors modifies pubertal development in male rats.
In conclusion, these results demonstrate that activation of AMPA receptors inhibits PRL release in prepubertal male rats, probably through a hypothalamic mechanism involving the release of dopamine.
